Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$3.27 - $8.76 $68,097 - $182,427
-20,825 Closed
0 $0
Q1 2022

May 10, 2024

BUY
$7.56 - $14.3 $157,437 - $297,797
20,825 New
20,825 $170,000
Q1 2022

Jun 20, 2023

BUY
$7.56 - $14.3 $157,437 - $297,797
20,825 New
20,825 $170,000
Q1 2022

Mar 22, 2023

BUY
$7.56 - $14.3 $56,246 - $106,392
7,440 Added 55.58%
20,825 $170,000
Q1 2022

May 12, 2022

BUY
$7.56 - $14.3 $56,246 - $106,392
7,440 Added 55.58%
20,825 $171,000
Q4 2021

Jun 21, 2023

BUY
$12.24 - $21.25 $163,832 - $284,431
13,385 New
13,385 $191,000
Q3 2021

Jun 21, 2023

BUY
$16.69 - $26.05 $223,395 - $348,679
13,385 New
13,385 $257,000
Q2 2021

May 17, 2024

BUY
$18.15 - $27.75 $69,314 - $105,977
3,819 Added 39.92%
13,385 $338,000
Q2 2021

Jun 21, 2023

BUY
$18.15 - $27.75 $242,937 - $371,433
13,385 New
13,385 $338,000
Q2 2021

Mar 22, 2023

BUY
$18.15 - $27.75 $69,314 - $105,977
3,819 Added 39.92%
13,385 $338,000
Q2 2021

Aug 16, 2021

BUY
$18.15 - $27.75 $69,314 - $105,977
3,819 Added 39.92%
13,385 $339,000
Q1 2021

May 17, 2024

BUY
$20.71 - $51.02 $198,111 - $488,057
9,566 New
9,566 $235,000
Q1 2021

Jun 26, 2023

BUY
$20.71 - $51.02 $198,111 - $488,057
9,566 New
9,566 $235 Million
Q4 2020

Jun 22, 2023

BUY
$21.84 - $44.0 $208,921 - $420,904
9,566 New
9,566 $350,000
Q3 2020

Jun 26, 2023

BUY
$13.63 - $24.12 $130,384 - $230,731
9,566 New
9,566 $207,000
Q2 2020

May 24, 2024

BUY
$7.65 - $14.11 $73,179 - $134,976
9,566 New
9,566 $124 Million
Q2 2020

Jun 26, 2023

BUY
$7.65 - $14.11 $73,179 - $134,976
9,566 New
9,566 $124,000
Q2 2020

Mar 22, 2023

BUY
$7.65 - $14.11 $73,179 - $134,976
9,566 New
9,566 $124,000
Q2 2020

Aug 14, 2020

BUY
$7.65 - $14.11 $73,179 - $134,976
9,566 New
9,566 $124,000

Others Institutions Holding PSNL

About Personalis, Inc.


  • Ticker PSNL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 45,918,400
  • Market Cap $171M
  • Description
  • Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or pla...
More about PSNL
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.